Completed PHASE2 INTERVENTIONAL 3-arm NCT00504660

6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients

Combination of 6-Thioguanine, Capecitabine, Celecoxib and Temozolomide or CCNU for Recurrent Anaplastic Glioma and Glioblastoma Multiforme

Sponsor: M.D. Anderson Cancer Center

Conditions Anaplastic Glioma of Brain Brain Cancer Glioblastoma Multiforme

Interventions 6-Thioguanine Capecitabine Celecoxib (Celebrex) Lomustine Temozolomide

Updated 7 times since 2017 Last updated: Dec 6, 2011 Started: Sep 30, 2003 Primary completion: Aug 31, 2010 Completion: Aug 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Anaplastic Glioma of Brain and Brain Cancer and is currently completed. M.D. Anderson Cancer Center leads this study, which shows 7 recorded versions since 2003 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Sep 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

M.D. Anderson Cancer Center

Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States